40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?
Autor: | Anna Majewska, Beata Mlynarczyk-Bonikowska |
---|---|
Rok vydání: | 2022 |
Předmět: |
Herpes Genitalis
Organic Chemistry Infant Newborn Acyclovir Cytomegalovirus HIV Infections Herpes Simplex Herpesviridae Infections General Medicine Antiviral Agents Herpes Zoster Catalysis Computer Science Applications Inorganic Chemistry Pregnancy Humans Female Physical and Theoretical Chemistry Molecular Biology Spectroscopy |
Zdroj: | International Journal of Molecular Sciences. 23:3431 |
ISSN: | 1422-0067 |
DOI: | 10.3390/ijms23073431 |
Popis: | Herpes simplex virus types 1 and 2 HSV1 and 2, namely varicella-zoster VZV and cytomegalovirus CMV, are among the most common pathogens worldwide. They remain in the host body for life. The course of infection with these viruses is often asymptomatic or mild and self-limiting, but in immunocompromised patients, such as solid organ or bone marrow transplant recipients, the course can be very severe or even life-threatening. Unfortunately, in the latter group, the highest percentage of infections with strains resistant to routinely used drugs is observed. On the other hand, frequent recurrences of genital herpes can be a problem even in people with normal immunity. Genital herpes also increases the risk of acquiring sexually transmitted diseases, including HIV infection and, if present in pregnant women, poses a risk to the fetus and newborn. Even more frequently than herpes simplex, congenital infections can be caused by cytomegalovirus. We present the most important anti-herpesviral agents, the mechanisms of resistance to these drugs, and the associated mutations in the viral genome. Special emphasis was placed on newly introduced drugs such as maribavir and brincidofovir. We also briefly discuss the most promising substances in preclinical testing as well as immunotherapy options and vaccines currently in use and under investigation. |
Databáze: | OpenAIRE |
Externí odkaz: |